Tonix Pharmaceuticals Holding Corp. [NASDAQ: TNXP] closed the trading session at $0.70 on 09/19/22. The day’s price range saw the stock hit a low of $0.6875, while the highest price level was $0.7927. The company report on September 15, 2022 that Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Rejection in Allograft and Xenograft Transplantation in Animal Models at the International Congress of The Transplantation Society (TTS 2022).
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
TNX-1500 Treatment Prevents Organ Rejection and Preserves Function for Both Allograft and Xenograft Transplants in Animal Studies.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced data from three oral presentations by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital Center at the 29th International Congress of The Transplantation Society (TTS 2022) held September 10-14, 2022 in Buenos Aires, Argentina. The data involve studies of Tonix’s TNX-1500 (Fc modified anti-CD40L monoclonal antibody) product candidate in development for the prevention of organ transplant rejection. The molecular target of TNX-1500 is CD40-ligand (CD40L), which is also known as CD154. Copies of the presentations are available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.
The stocks have a year to date performance of -93.84 percent and weekly performance of -27.09 percent. The stock has been moved at -90.82 percent over the last six months. The stock has performed -49.64 percent around the most recent 30 days and changed -60.17 percent over the most recent 3-months.
If compared to the average trading volume of 7.13M shares, TNXP reached to a volume of 5490963 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Tonix Pharmaceuticals Holding Corp. [TNXP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TNXP shares is $38.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TNXP stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Noble Capital Markets have made an estimate for Tonix Pharmaceuticals Holding Corp. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 18, 2022. The new note on the price target was released on April 18, 2019, representing the official price target for Tonix Pharmaceuticals Holding Corp. stock. Previously, the target price had yet another raise to $6, while ROTH Capital analysts kept a Buy rating on TNXP stock.
The Average True Range (ATR) for Tonix Pharmaceuticals Holding Corp. is set at 0.09 The Price to Book ratio for the last quarter was 0.06, with the Price to Cash per share for the same quarter was set at 3.01.
TNXP stock trade performance evaluation
Tonix Pharmaceuticals Holding Corp. [TNXP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -27.09. With this latest performance, TNXP shares dropped by -49.64% in over the last four-week period, additionally sinking by -90.82% over the last 6 months – not to mention a drop of -96.44% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TNXP stock in for the last two-week period is set at 25.49, with the RSI for the last a single of trading hit 18.63, and the three-weeks RSI is set at 30.33 for Tonix Pharmaceuticals Holding Corp. [TNXP]. The present Moving Average for the last 50 days of trading for this stock 1.3045, while it was recorded at 0.8356 for the last single week of trading, and 5.2371 for the last 200 days.
Tonix Pharmaceuticals Holding Corp. [TNXP]: An insightful look at the core fundamentals
Return on Equity for this stock declined to -60.25, with Return on Assets sitting at -54.43.
Tonix Pharmaceuticals Holding Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.10 and a Current Ratio set at 12.10.
Tonix Pharmaceuticals Holding Corp. [TNXP]: Insider Ownership positions
There are presently around $3 million, or 10.60% of TNXP stock, in the hands of institutional investors. The top three institutional holders of TNXP stocks are: MORGAN STANLEY with ownership of 886,716, which is approximately 5130.129% of the company’s market cap and around 0.03% of the total institutional ownership; VANGUARD GROUP INC, holding 732,180 shares of the stock with an approximate value of $0.52 million in TNXP stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $0.45 million in TNXP stock with ownership of nearly 7.185% of the company’s market capitalization.
Positions in Tonix Pharmaceuticals Holding Corp. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 35 institutional holders increased their position in Tonix Pharmaceuticals Holding Corp. [NASDAQ:TNXP] by around 2,450,344 shares. Additionally, 61 investors decreased positions by around 1,669,222 shares, while 5 investors held positions by with 206,586 shares. The mentioned changes placed institutional holdings at 4,326,152 shares, according to the latest SEC report filing. TNXP stock had 14 new institutional investments in for a total of 1,049,009 shares, while 49 institutional investors sold positions of 503,685 shares during the same period.